2022 Year in Review: Cholangiocarcinoma

NEO-GAP investigators found neoadjuvant gemcitabine/cisplatin/nab-paclitaxel combination to be feasible and safe prior to curative-intent surgical resection in patients with intrahepatic cholangiocarcinoma.

Early data from the ReFocus trial indicated that RLY-4008 may be an effective new treatment for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.

Subanalysis of the phase 3 TOPAZ-1 trial found that durvalumab plus gemcitabine/cisplatin showed efficacy as a treatment regimen in patients with biliary tract cancer regardless of primary tumor location.

Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.

Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.

The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.

Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements.

Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.